Baudax Bio, Inc. Stock Price, News & Analysis

Baudax Bio, Inc. (NASDAQ:BXRX) announced the issuance of United States Patent No. 11,253,478 for its product ANJESO, covering new injectable meloxicam compositions. This patent, expiring in May 2030, reinforces exclusivity for ANJESO, which now has a total of six patents listed in the FDA's Orange Book. The patent aims to create a barrier against generic competitors. ANJESO is indicated for managing moderate to severe pain without the risks associated with opioids, backed by extensive clinical trials.

Baudax Bio (NASDAQ: BXRX) announced the pricing of a public offering of 3,508,772 shares of common stock, alongside warrants for the same amount. The offering is priced at $2.85 per share, with an expected gross proceeds of approximately $10 million before expenses. The warrants have an exercise price of $3.25 and will expire in five years. The funds are intended for the commercialization of ANJESO, pipeline development, and general corporate purposes. The offering is set to close around March 1, 2022, subject to customary conditions.

Baudax Bio (NASDAQ: BXRX) has initiated a proposed underwritten public offering of its common stock and warrants. The offering is intended to raise funds for the commercialization of ANJESO, pipeline development, and general corporate purposes. The offering is subject to market conditions, and a preliminary prospectus has been filed with the SEC. H.C. Wainwright & Co. is acting as the sole book-running manager. The company emphasizes that there is no assurance of completion or specific terms of the offering.

Baudax Bio (NASDAQ:BXRX) announced a 1-for-35 reverse stock split, effective February 16, 2022, to comply with Nasdaq's $1.00 minimum bid price requirement. The split reduces outstanding shares from approximately 101.6 million to about 2.9 million, maintaining par value at $0.01 per share. Shareholders will receive cash for any fractional shares. This move aims to enhance the stock's market price and attract new investors, with adjustments made to outstanding stock options and warrants.

MALVERN, Pa., Jan. 4, 2022 - Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation will be available for on-demand listening starting January 10, 2022, at 7:00 a.m. ET on the company's website, with a replay available for 30 days afterward.

Baudax Bio specializes in developing innovative products for acute care, including ANJESO, a unique 24-hour intravenous NSAID for managing moderate to severe pain, alongside a promising pipeline of neuromuscular blocking agents.

Baudax Bio (NASDAQ:BXRX) announced on December 31, 2021, that its Compensation Committee approved stock option grants totaling 109,250 shares and restricted stock units covering 31,900 shares to 14 newly-hired employees. These grants, effective December 29, 2021, are compliant with Nasdaq Rule 5635(c)(4), serving as inducements for employment. The options will have an exercise price of $0.22 per share, vesting over four years. Baudax Bio focuses on acute care products and is known for ANJESO, the first IV COX-2 preferential NSAID for pain management.

Baudax Bio (NASDAQ:BXRX) has announced a definitive agreement to sell 42,289.3 shares of convertible preferred stock and warrants for gross proceeds of $4.2 million. The preferred stock, convertible into 16,915,720 shares of common stock at $0.25 each, and warrants at $0.32, aim to support the commercialization of ANJESO and other pipeline activities. The transaction, expected to close on December 28, 2021, involves the establishment of voting rights, enabling preferred stockholders to influence decisions on a proposed reverse stock split.

MALVERN, Pa., Nov. 15, 2021 - Baudax Bio, a pharmaceutical company focused on developing innovative acute care products, announced that its CEO Gerri Henwood will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The chat will be available for on-demand listening starting November 22, 2021, at 10:00 a.m. ET on the company's website. Baudax Bio's lead product, ANJESO, is the first 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain.

Baudax Bio (NASDAQ:BXRX) announced the completion of a dose-escalation study for BX-1000, an intermediate-duration neuromuscular blocking agent (NMB), which was generally well tolerated. The study involved 58 healthy volunteers and monitored rapid muscle paralysis and subsequent recovery. The company is preparing to submit a clinical study report to the FDA and plans to advance BX-2000 and BX-3000 into clinical studies in 2022, after completing toxicology studies. These NMBs can reduce recovery times in surgical settings, promising significant cost savings for healthcare facilities.